
Aerovate Therapeutics Inc
NASDAQ:AVTE

Intrinsic Value
The intrinsic value of one
AVTE
stock under the Base Case scenario is
94.94
USD.
Compared to the current market price of 93.8 USD,
Aerovate Therapeutics Inc
is
Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Aerovate Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Aerovate Therapeutics Inc
Balance Sheet Decomposition
Aerovate Therapeutics Inc
Current Assets | 80.1m |
Cash & Short-Term Investments | 78.6m |
Other Current Assets | 1.5m |
Non-Current Assets | 215k |
PP&E | 215k |
Free Cash Flow Analysis
Aerovate Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Aerovate Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-74.3m
USD
|
Operating Income
|
-74.3m
USD
|
Other Expenses
|
4.7m
USD
|
Net Income
|
-69.6m
USD
|
AVTE Profitability Score
Profitability Due Diligence
Aerovate Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
Aerovate Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
AVTE Solvency Score
Solvency Due Diligence
Aerovate Therapeutics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Score
Aerovate Therapeutics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVTE Price Targets Summary
Aerovate Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
AVTE
is 83.3 USD
with a low forecast of 70.7 USD and a high forecast of 110.25 USD.
Dividends
Current shareholder yield for AVTE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
AVTE
stock under the Base Case scenario is
94.94
USD.
Compared to the current market price of 93.8 USD,
Aerovate Therapeutics Inc
is
Undervalued by 1%.